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Abstract 
BACKGROUND: In recent times, scientists have found new treatments for colorectal cancer patients.  
AIM: The study is to evaluate the efficacy and toxicity of triplet combination chemotherapy of 5-
fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) for patients with metastatic colorectal cancer in 
stage IV. 
METHODS: Uncontrolled clinical trial carried on 39 stage IV colorectal cancer patients. 
RESULTS: The overall response rate of the treatment was 79.4%. The average progression-free survival was 
13.4 ± 9 months. The overall survival rate at 12th month and 24th month were 90% and 76%, respectively. The 
proportion of granulocytopenia was 48.9%, no grade 3 or 4. Side effect beyond hematology was most seen in 
hepatic toxicity with 52.5%, mainly at grade 1. Vomiting was 18.3%, all at grade 1. Other adverse event was very 
low at percentage. 
CONCLUSIONS: The triplet combination FOLFOXIRI chemotherapy improves the outcome of patients with 
metastatic colorectal cancer regarding rate of response, overall survival rate and progression-free survival, and 
the level of toxicity was acceptable. 
 
 
 
 
 
Introduction 
 
Colorectal cancer is a common type of 
gastrointestinal cancer. The disease tends to increase 
in recent times. Treatment of metastatic colorectal 
cancer is still difficult, with overall survival (OS) and 5-
year survival rate reported of 16-25 months and 11%, 
respectively [1], [2]. At present, 5-fluorouracilimines, 
oxaliplatin and irinotecan are still three "backbone" 
drugs to the treatment for metastatic colorectal 
cancer. 
A meta-analysis presented that the increase 
of overall survival rate significantly associate with the 
use of all 5-fluorouracil, oxaliplatin and irinotecan over 
the total duration of treatment [3]. Currently, in 
accordance with recommendation by many cancer 
organizations around the world, these three drugs are 
used step by step through two-drug regimen 
(FOLFOX/XELOX, FOLFIRI/XELIRI). However, not all 
100% of patients are treated with all 3 these drugs 
because some patients abandon the following 
treatment lines, or their condition does not allow 
second-line treatment. 
Thus, the idea of using all three drugs from 
the first-line treatment was sprouted more than 10 
years ago. In 2002, the first two Phase II studies 
reported the efficacy and safety of the combination of 
Oxaliplatin/Irinotecan/5-FULV (FOLFOXIRI) at the first 
stage [4]. Subsequently, many phase III studies were 
performed with satisfactory results of this regimen. 
Since 2010, FOLFOXIRI were recommended in 
NCCN (National Comprehensive Cancer Network) 
Clinical Practice Guidelines in Oncology [5]. 
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In Vietnam, the rateof colorectal cancer ranks 
4
th
 in men and 6
th
 in women [6]. FOLFOXIRI regimen 
is gradually being introduced at some oncology 
facilities due to its efficacy and feasibility. However, 
since then there was no clinical trial established to 
evaluate the effectiveness as well as toxicity of 
FOLFOXIRI in Vietnamese patients with metastatic 
colorectal cancer.  
Therefore, we carried out this work with the 
aim of performing an initial review in relation to the 
efficacy and toxicity of FOLFOXIRI in treatment for 
patients with metastatic colorectal cancer in stage IV. 
 
 
Materials and Methods 
 
Study design 
This study was a single-arm, uncontrolled 
prospective clinical trial. All eligible patients were 
selected from October 2013 to September 2014 in the 
Oncology and Palliative Care Department, Hanoi 
Medical University Hospital. 
 
Patient selection and study process 
Main eligibility criteria were as followed: 
patients were diagnosed with metastatic unresectable 
colorectal adenocarcinoma; age from 20 to 75 years; 
Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) score of 0 or 1; the patients 
were treated by at least 3 cycles of FOLFOXIRI in the 
first-line treatment (Table 1); liver, kidney and 
hematological functions before treatment were in 
normal limits; did not suffer from diseases with near-
death risk and other chronic diseases. General 
information was collected by questioning patients and 
their family member to record age, gender, medical 
history, reasons of hospitalization, signs and 
symptoms of disease. Pre-treatment assessment 
included physical examination, performance status 
evaluation, complete blood profile, CEA level 
measurement, colonoscopy, X-ray imaging or CT 
(computed tomography) scan, abdominal CT scan 
and/or ultrasound, electrocardiogram and any other 
applicable method to examine metastatic sites. In the 
period of treatment, a physical examination was 
conducted once in two weeks. Metastatic sites were 
re-examined once within 8 weeks. Abdominal CT scan 
or MRI was demanded in order to evaluate liver and 
abdominal metastases. 
Table 1: Treatment of FOLFOXIRI chemotherapy at first-line 
with specific dosage 
Dosage Day of receiving 
Irinotecan: 165 mg/m2, intravenous infusion for 1 hour. Day 1, 15 
Oxaliplatin: 85 mg/m2, intravenous infusion for 2 hours Day 1, 15 
Calcium folinat 200 mg/m2, intravenous infusion for 2 hours  Day 1, 15 
5FU 3200 mg/m2, continuous intravenous infusion during 48 hours  Day 1, 2, 3, 15, 16, 17 
Note: The regimen was repeated once per 2 weeks. 
Evaluation of treatment response was made 
in accordance with RECIST (Response Evaluation 
Criteria in Solid Tumors) criteria version 1.1 [7]. 
Overall response = Complete response + partly 
response [7]. The adverse event of FOLFOXIRI 
chemotherapy were observed weekly and categorized 
in accordance with standard National Cancer Institute 
Common Terminology Criteria for Adverse Events 
version 4.0. Patients with disease stability or 
continuous response after 6 cycles were shifted to 
maintenance phase with oral Capecitabine (Xeloda). 
During maintenance treatment, patients were re-
examined before Capecitabine administration. 
Progression Free Survival is estimated in the period of 
time between the time the study starts and the time of 
disease progression. Overall survival was calculated at 
12-month and 24-month. 
 
Statistics 
All collected data were analyzed and 
measured by SPSS 22.0 software. Progression-free 
survival (PFS) and overall survival (OS) were 
estimated by the Kaplan-Meier method from the day 
of treatment started. Dichotomous variables were 
analyzed by using Chi-square test and median values 
compa. The p values < 0.05 were recognized 
statistically significant. 
 
Ethical 
This study is completely voluntary and is 
aimed at improving the quality of treatment, not for 
any other purpose. Patients who have met the 
selection criteria will be explained in detail about the 
study, patients who agree to participate in the study 
will be signed on a volunteer to participate in the 
study. All details about the patient's condition are 
encrypted and confidential. The patient has the right 
to withdraw from the study. 
 
 
Results 
 
A total of 39 unresectable metastatic 
colorectal cancer patients were recruited to the study. 
There were 26 males and 13 females, with a median 
age of 52.9 years (range 25-70). Half of the 
participants had taken chemotherapy for their disease 
previously. The most common reason for 
hospitalization was abdominal pain with 74.4%. 
Majority of patients were with PS-1 (82.1%), while 
performance status (PS) score of 0 accounted for 
percentage of 17.9%. Bowel obstruction was the most 
common symptom (43.6%), followed by papable 
abdominal mass of 20.5% at the time of diagnosis 
(Table 2). 
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Moderately differentiated adecarcinoma was 
responsible for two third of the study population, 
followed by participants having type of histopathology 
as mucinous adenocarcinoma. The peritoneum was 
more commonly found in patients with mucinous 
colorectal cancer (20.5%, compared with 5.1% of 
patients with moderately differentiated 
adenocarcinoma) (Table 2). 
Regarding primary tumor distribution, left-
sided colorectal cancer had the highest percentage of 
61.5%. Of which, primary tumors were more 
frequently distributed at sigmoid colon (41%) and liver 
(17.9%), other locations accounted for proportion of 
41.1%. Liver was the most prevalent distant 
metastatic site (64.1%), whereas patients with 
peritoneal metastasis and pulmonary metastasis were 
25.6% and 17.9%, respectively. Retroperitoneal lymph 
node occurred in 30.8% of metastatic colorectal 
patients. 26 patients (66.7%) had CEA levels of 
20ng/ml or below before treatment (Table 2). 
Table 2: Clinic-pathology features of metastatic colorectal 
cancer patients whose disease was not radically resectable 
Characteristics Percentage 
Gender 
Male 26 (66.7%) 
Female 13 (33.3%) 
Age 
Under 40 8 (20.5%) 
45-60 26 (66.7%) 
Over 65 5 (13.8%) 
Signs 
Abdominal pain 29 (74.4%) 
Hematochezia 10 (25.6%) 
Diarrhea 9 (23.1%) 
Performance status 
PS1 32 (82.1%) 
PS0 7 (17.9%) 
Symptoms 
Bowel obstruction 17 (43.6%) 
Fluid in the abdomen 1 (2,6%) 
Palpable abdominal mass 8 (20.5%) 
No symptom 13 (33.3%) 
Tumor location 
Sigmoid colon 16 (41%) 
Hepatic flexure 7 (18%) 
Other location 16 (41%) 
Distant metastatic site 
Liver metastasis 25 (64.1%) 
Pulmonary metastasis 7 (17.9%) 
Peritoneal metastasis 10 (25.6%) 
Retroperitoneal lymph node 12 (30.8%) 
No. of involved organs 
> 1 32 (82.1%) 
= 1 7 (17.9%) 
CEA concentration  
CEA > 20 ng/ml 13 (33.3%) 
CEA ≤ 20 ng/ml 26 (66.7%) 
Histopathology 
Moderately differentiated adenocarcinoma 26 (66.7%) 
Mucinous adenocarcinoma 13 (33.3%) 
 
 
Efficacy 
 All participating patients had measurable 
disease and were evaluated for response (Table 3). 
Table 3: Response rate of the treatment 
Response Percentage (%) 
Completely 2 (5.9%) 
Partially 25 (73.5%) 
Disease stability 4 (11.8%) 
Disease progression 3 (8.8%) 
 
After 3 cycles, we recorded 5.1% of patients 
who responded fully after 3 cycles and the majority of 
patients had partial response (76.9%); 5.1% of 
patients with progressed disease. After 6 cycles, five 
patients discontinued the chemotherapy prematurely 
because of disease progression after 3 cycles and 
geographical distance. According to Table 3, 25 
patients (73.5%) achieved partial remission and 2 
cases (5.9%) obtained a complete response, 
therefore, the rate of overall response and disease 
control were 79.4% and 91.2%, respectively. The 
median dosage intensity of irinotecan, oxaliplatin and 
5-FU used in the treatment for 39 colorectal cancer 
patients were 83.7%, 83.08% and 84.33%, 
respectively. 
 
Figure 1: Progression-free survival 
 
 After 36 months of follow-up, the progression-
free survival in our study was calculated as 13.4 ± 9 
months (Figure 1). The overall survival rate at 12th 
month was 90% and 24th month was 76% (Figure 2). 
 
Figure 2: Overall survival rate 
 
All patients in the study were assessable for 
the safety of treatment. The most prevalent adverse 
events included neutropenia, thrombocytopenia, 
anemia, vomiting, diarrhea, stomatitis, hepatic toxicity, 
peripheral neurotoxicity. Nevertheless, most toxicity 
complications were at grade 1 or 2, and grade 3 or 4 
was commonly seen in neutropenia. Of which, 
granulocytopenia of grade 1/2 occurred in 25.5% of 
patients, while grade 3 and 4 occupied a lower rate of 
14.1% and 9.3%, respectively. Thrombocytopenia and 
anemia accounted for very low percentage of 3.2% 
and 8.3%, mainly at grade 1. Liver toxicity was the 
most prevalent non-hematological adverse event and 
accounted for the highest proportion of 52.5%, 
followed by vomiting and diarrhea with the figure of 
18.3% and 6.9%, respectively. All of them were 
scored at grade 1/2 (Table 4). 
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Table 4: Adverse Event of FOLFOXIRI regimen 
Adverse Event Grade 0 (%) Grade 1-2 (%) Grade 3-4 (%) 
Granulopenia 51.1 25.5 23,4 
Thrombocytopenia 96.8 3.2 0 
Anemia 91.7 8.3 0 
Vomiting 74.23 23 2.67 
Diarrhea 93.1 6.9 0 
Oral toxicity 96.57 3.63 0 
Liver toxicity 47.5 52.5 0 
 
 
 
Discussion 
 
In recent times, the development of 
chemotherapy in treatment for patients with colorectal 
cancer has led to considerable benefit regarding 
antitumor activity and efficacy [5]. Documents showed 
that the best outcomes are obtained from patients 
who received all three main active substances (5-FU, 
irinotecan and oxaliplatin), but that in a sequential 
strategy only 60% to 80% of patients are able to 
continue the second-line treatments and thus, to be 
able to expose to all these three agents. These 
considerations assist the procedure to improve 
potentially more active first-line regimens which put 5-
FU with both irinotecan and oxaliplatin. Thus, we 
conducted the study to evaluate effectiveness combo 
of irinotecan, oxaliplatin and 5-FU/LV (FOLFOXIRI), 
orderly. 
In our research, the overall response rate was 
79.4%. Of which, there were 5.1% of patients with full 
response, 73.5% with partial response, 11.8% with 
stable disease and 5.9% with progressive disease. 
Consequently, the rate of disease control was 
calculated as 91.2%. The overall response rate is 
among the highest findings which were presented in 
previous study on any chemotherapy regimens for 
treatment of metastatic colorectal cancer [4], [8], [9], 
[10]. The median dose intensities were 83.7% with 
Irinotecan, 83.08% with Oxaliplatinand 84.33% with 5-
FU. This is the lowest dose intensity of chemotherapy 
compared with those four reference studies, except 
for Souglakos et al.’s study [8]. Regarding to patients’ 
characteristics, based on three main factors: median 
age, prevalence of patients treated with chemotherapy 
before, severity of disease, our patients group 
presented a younger median age (54 years), the 
second lowest number of patients with metastases > 1 
(16.7%, just behind the figure of Azmy et al.’s study 
with 9%), and approximately 50% of patients had 
been taken with chemotherapy previously (middle-
ranking among 4 cited studies). Thus, the 
characteristics of our studied population were 
relatively more favorable than those of other groups in 
mentioned studies. 
During a follow-up period of 36 months, our 
study showed that the median progression-free 
survival was recorded as 13.37 ± 9 months. This 
result was comparable to foreign studies using the 
same regimen. Particularly, Falcone et al.’s study, 
(2002) revealed a median progression-free survival of 
10.4 months while Souglakos et al.’s study reported 
the progression-free survival of 13 months on average 
[4], [8]. Furthermore, in comparison with other 
regimens, FOLFOXIRI increased PFS by about 3 
months, and decreased the risk of early disease 
progression by halfThe 12th month and 24th month 
overall survival rate was 90% and 76%, respectively. 
A notable disadvantage of FOLFOXIRI is 
tohave many side-effects, but in an acceptable level. 
Neutropenia was the most common hematological 
toxic effect with proportion of 48.9%. In particular, the 
incidence of grade 1/2 granulocytopenia was 25.5% 
while grade 3/4 was found in 23.4% of patients. There 
was no case of fever caused by neutropenia. 
Interestingly, neutropenia was one of the adverse 
event with the highest rate in studies conducted by 
Falcone et al., (2002)’s which suggested that 14% of 
patients had at least one episode of neutropenia fever 
[4], and Souglakos et al., (2002) which found that 
grade 3 and grade 4 neutropenia happended in 14 
patients (45%), two patients had neutropenia fever 
(6%) [8]. Compared with mentioned authors, our result 
of neutropenia was somewhat lower. In our study, 
patients were screened for blood count routinely on 
day 8 after chemotherapy. Cases with grade 2 or 
above were injected with leukocyte stimulants and 
closely observed, daily white blood cell counts were 
measured to administer leukocyte-stimulating drugs if 
necessary, until blood cound reached over 2000 white 
blood cells/ml. In addition, dosage adjustment for 
each patient was based on level of granulocytopenia 
in the period of treatment. Cases with grade 3 
granulocytopenia were isolated in sterile rooms and 
broad-spectrum antibiotic prophylaxis was used until 
white blood cells increased to above 2000/ml. 
Regarding anemia, the rates of anemia and 
thrombocytopenia in our study were 8.3% and 3.2%, 
respectively. Most of side effects of anemia (6.5%) 
and thrombocytopenia were at grade 1. The rate of 
grade 2 anemia was very low with 2.3% and these 
side effects at grade 3 and 4 did not appear in the 
study. Also, the percentages of anemia and 
thrombocytopenia of foreign studies were very low (< 
10%) [11], [12]. The three drugs Oxaliplatin, 5-FU and 
Irinotecan have unclear effect on thrombocytopenia 
occurrence. Regarding anemia, only oxaliplatin can 
cause a small erythropoietic anemia because a small 
fraction (~ 7%) of oxaliplatin penetrate into red blood 
cells and break down the red blood cells after 48 
days. Nevertheless, because only a small proportion 
of oxaliplatin can get into red blood cells, the levels of 
anemia of regimens containing oxaliplatin in general 
and of FOLFOXIRI in particular are not high. 
Vomiting during chemotherapy occurred in 42 
cases. However, no incidence of vomiting at grade 4, 
grade 3 occurred in 2.67% of the patients. The 
remaining was mainly infusions causing vomiting at 
grade 1 (74.23%) and grade 2 (23%). The toxicity rate 
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was lower than Falcone et al.'s study, in which the 
incidence of vomiting was 60% for grade 1, 53% for 
grade 2 and 13% for grade 3 [4]. The causes of this 
type of vomiting are usually related to psychological 
factors which stimulate pneumogastric nerve to cause 
vomiting. To solve this problem, we usually use 
supplements of pills (Diazepam) for patients with a 
history of severe vomiting in the previous infusion. In 
addition to using the 5-HT3 class of anti-vomiting 
medication, we also combined two other classes in a 
routine way: Corticosteroids (dexamethasone) have 
anti-vomiting mechanism on the central nervous 
system; Primperan has anti-vomiting mechanism by 
D4 receptor blockade. Several severe vomiting cases 
(grade 3) were also given Haloperidol, a 
chemotherapy-induced P-receptor blocker in the CTZ 
(chemo-trigger zone). 
The incidence of diarrhea in our study group 
was 6.9%. Most patients developed diarrhea at later 
time (after 24 hours of chemical infusion). There was 
no case of diarrhea in grade 3 or 4. By contrast, 
Souglakos et al., treated on 31 stage IV colorectal 
cancer patients with the similar regimen and found 
that grade 3 and 4 diarrhea was presented in 10 
cases (32%) [8]. Besides, the rate of grade 3, 4 
diarrhea in Falcone et al.’s research (2007) was 20%, 
with no significant difference from FOLFIRI group [10]. 
Irinotecan, in addition to be Topoisomerase II enzyme 
inhibitor, inhibit Acetylcholinesterase, an enzyme that 
decomposes neurotransmitter of Acetylcholin 
receptor. Therefore, using Irinotecan will stimulate 
parasympathetic nervous system which intensifies 
bowel movement and results in diarrhea. All of our 
patients are taking Atropin to prevent this side effect. 
Depending on the severity of patient’s diarrhea, 
Atropin is added during infusion. 
Three-point six three percent of patients with 
oral toxicity had been detected in this study and all 
were at grade 1. FOLFOXIRI regimen not using bolus 
5-FU as a feature causes low rate of stomatitis. 
Studies of Peeters M et al., (2010) [13] and Douillard 
JY et al., (2000) [14] also had a low incidence of this 
toxicity (below 5%) [13], [14]. Cases with oral toxicity 
was detected and treated early, which limited 
significantly the severity of this unwanted effects. 
The most prevail non-hematological adverse 
event was liver toxicity, accounting for 52.5% of 
patients treated by FOLFOXIRI, by most of them were 
at grade 1 (50%), followed by grade 2 with only 2.5%. 
Similarly, liver toxicity in majority of foreign studies 
amounted to the highest percentage at grade 1 while 
the figure of grade 2 toxicity was very small [15], [16]. 
Of three drugs used in this study, Oxaliplatin is 
metabolized and excreted mainly in kidney so there is 
no effect on the liver. 5-FU and irinotecan are 
metabolised and excreted primarily in the liver, which 
can cause hepatitis due to the drug. However, the 
severity of hepatitis is usually mild and self-healing 
after chemotherapy discontinuation. In the period of 
treatment, we focussed on the use of infusion after 
chemotherapy to improve liver function, which helps 
reduce liver enzymes.  
In conclusion, the FOLFOXIRI chemotherapy 
is a highly effective regimen demonstrated by an 
increase in response rate, progression-free survival 
and has side-effects at manageable and well tolerated 
levels during first-line treatment of metastatic 
colorectal cancer. The regimen needs to be 
conducted more in study with a larger sample size 
and a broader scope to prove its effectiveness and 
safety before being widely applied in hospitals across 
the country. 
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